Comparar métodos

	Cuestionario de Calidad de Vida en Rinoconjuntivitis	Sinonasal Outcome Test-22
Campo	Neumología	Neumología
Familia	Process / pipeline	Process / pipeline
Año de origen	1996	2009
Autor original	Elizabeth F. Juniper, McMaster University	Claire Hopkins, King's College London
Tipo	Self-report questionnaire	Self-report questionnaire
Fuente seminal	Juniper, E. F., Guyatt, G. H., Streiner, D. L., & King, D. R. (1996). Clinical validation and responsiveness of three scales developed to measure the effect of allergic rhinitis on quality of life. Journal of Clinical Epidemiology, 49(3), 339-347.	Hopkins, C., Gillett, S., Slack, R., Lund, V. J., & Browne, J. P. (2009). Psychometric validity of the 22-item Sinonasal Outcome Test. Clinical Otolaryngology, 34(5), 447-454.
Alias	RQLQ, Rhinoconjunctivitis QoL	SNOT-22, SNOT
Relacionados	5	5
Resumen	The RQLQ is a 28-item disease-specific quality-of-life instrument developed by Juniper and colleagues at McMaster University in 1996 to assess the impact of allergic rhinitis and allergic conjunctivitis on daily functioning. It captures symptom burden and activity limitation across seven domains: sleep, non-nose/eye symptoms, practical problems, nasal symptoms, eye symptoms, activity limitation, and emotional function. The RQLQ is the preferred outcome measure in allergic rhinitis clinical trials and is widely used in allergy and immunology practice to track treatment response.	The SNOT-22 is a 22-item disease-specific quality-of-life questionnaire designed to assess sino-nasal symptoms and their functional impact on patients with chronic rhinosinusitis, nasal polyposis, and allied conditions. Developed by Hopkins and colleagues at King's College London in 2009, it has become the most widely used instrument for measuring sino-nasal disease burden in clinical trials and rhinological practice. The SNOT-22 provides rapid, patient-centered assessment of both nasal-specific symptoms (congestion, drainage, sneezing) and general health impacts (sleep, headache, concentration).